---
figid: PMC5823630__oncotarget-09-8810-g006
figtitle: Anti-estrogens mitigate mTORC1 inhibitor-induced activation of PI3K/AKT
organisms:
- NA
pmcid: PMC5823630
filename: oncotarget-09-8810-g006.jpg
figlink: /pmc/articles/PMC5823630/figure/F6/
number: F6
caption: Depicted is the canonical signaling pathway in which ligand-activated IGF-1R/InsR
  homo- and hetero-dimers phosphorylate IRS-1/2 at Tyr sites, creating docking sites
  for p85/PI3K that derepress p110/PI3K. p110/PI3K converts PIP2 to PIP3, and PIP3
  enables recruitment of PH domain-containing proteins (e.g., AKT, PDK1) to the cytoplasmic
  face of the plasma membrane. PDK1 and mTORC2 phosphorylate AKT, and activated AKT
  in turn signals through the TSC1/2 complex to activate mTORC1. mTORC1 and its phospho-activated
  substrate p70S6K phosphorylate IRS-1/2 at Ser residues to promote proteasomal degradation
  of IRS-1/2, creating a negative feedback loop. Inhibition of mTORC1 with RAD001
  blocks such negative feedback, leading to increased IRS-1/2/PI3K/AKT activation.
  ER drives the expression of IGF-1R and IRS-1/2, which are downregulated by anti-estrogen
  treatment. Thus, anti-estrogens mitigate mTORC1 inhibitor-induced activation of
  PI3K/AKT in ER+ breast cancer cells.
papertitle: Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation
  of PI3K/AKT in ER+ breast cancer.
reftext: Wei Yang, et al. Oncotarget. 2018 Feb 6;9(10):8810-8822.
year: '2018'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9707562
figid_alias: PMC5823630__F6
figtype: Figure
organisms_ner:
- Homo sapiens
redirect_from: /figures/PMC5823630__F6
ndex: ef3a87f9-dec7-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5823630__oncotarget-09-8810-g006.html
  '@type': Dataset
  description: Depicted is the canonical signaling pathway in which ligand-activated
    IGF-1R/InsR homo- and hetero-dimers phosphorylate IRS-1/2 at Tyr sites, creating
    docking sites for p85/PI3K that derepress p110/PI3K. p110/PI3K converts PIP2 to
    PIP3, and PIP3 enables recruitment of PH domain-containing proteins (e.g., AKT,
    PDK1) to the cytoplasmic face of the plasma membrane. PDK1 and mTORC2 phosphorylate
    AKT, and activated AKT in turn signals through the TSC1/2 complex to activate
    mTORC1. mTORC1 and its phospho-activated substrate p70S6K phosphorylate IRS-1/2
    at Ser residues to promote proteasomal degradation of IRS-1/2, creating a negative
    feedback loop. Inhibition of mTORC1 with RAD001 blocks such negative feedback,
    leading to increased IRS-1/2/PI3K/AKT activation. ER drives the expression of
    IGF-1R and IRS-1/2, which are downregulated by anti-estrogen treatment. Thus,
    anti-estrogens mitigate mTORC1 inhibitor-induced activation of PI3K/AKT in ER+
    breast cancer cells.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - IGF1
  - SERPINA4
  - AKT1
  - AKT2
  - AKT3
  - PDK1
  - PDPK1
  - IRS2
  - IRS1
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - CUX1
  - SART3
  - ARHGEF7
  - CBFA2T2
  - PPP1R13B
  - PPP1R12C
  - MAPKAP1
  - MTOR
  - RICTOR
  - MLST8
  - RPTOR
  - RPS6KB1
  - RPS6KB2
  - EIF4EBP1
  - IGF1R
  - INSR
  - INSRR
  - estrogen
---
